Medical University of Graz

Reflow Medical Receives CE Mark for Bare Temporary Spur Stent System for Treating de novo or Restenotic Below-the-Knee (BTK) Lesions

Retrieved on: 
Tuesday, January 16, 2024

Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System .

Key Points: 
  • Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE (Conformité Européenne) Mark certification in the European Union for the Bare Temporary Spur Stent System .
  • The device is intended to treat de novo or restenotic lesions in the infrapopliteal arteries with a commercially available drug-coated balloon (DCB) to enhance drug absorption.
  • View the full release here: https://www.businesswire.com/news/home/20240116803175/en/
    The Bare Temporary Spur Stent System is a unique clinical solution known as Retrievable Stent Therapy, or RST.
  • The Bare Temporary Spur Stent System is a unique clinical solution intended to provide stent-like results while leaving no metal behind.

Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers

Retrieved on: 
Monday, July 3, 2023

Recent data shows that, despite advances in recent years, the time from onset of symptoms to diagnosis of pulmonary arterial hypertension, for example, is more than 2 years1.

Key Points: 
  • Recent data shows that, despite advances in recent years, the time from onset of symptoms to diagnosis of pulmonary arterial hypertension, for example, is more than 2 years1.
  • These advances represent a promising opportunity to improve outcomes for people with pulmonary arterial hypertension.
  • Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension.
  • The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment.

Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology

Retrieved on: 
Tuesday, December 6, 2022

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz.

Key Points: 
  • Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz.
  • Alastair Johnson, Chief Professional Services Officer at Congenica, said: We are delighted to be part of this exciting project.
  • Our oncology application will offer cancer patients across Europe the utmost benefit from NGS data and rapid access to personalised healthcare.
  • Congenica was selected for the second stage of this project in October 2022 from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.

Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Retrieved on: 
Thursday, December 1, 2022

This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.

Key Points: 
  • This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.
  • Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients' diagnostics.
  • BC Platforms, Euformatics, and Oncompass Medicine, have been working on designing the solution.
  • The consortium of BC Platforms, Euformatics and Oncompass Medicine was selected from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.

Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Retrieved on: 
Thursday, December 1, 2022

This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.

Key Points: 
  • This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.
  • Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients' diagnostics.
  • BC Platforms, Euformatics, and Oncompass Medicine, have been working on designing the solution.
  • The consortium of BC Platforms, Euformatics and Oncompass Medicine was selected from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.

Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease

Retrieved on: 
Wednesday, September 14, 2022

These statements may be identified by the use of forward-looking words such as anticipate, believe, forecast, estimated, and intend, among others.

Key Points: 
  • These statements may be identified by the use of forward-looking words such as anticipate, believe, forecast, estimated, and intend, among others.
  • These forward-looking statements are based on Hepion Pharmaceuticals current expectations and actual results could differ materially.
  • There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.
  • The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes.

Lifespin Significantly Expands its Proprietary Database of Human Health Profiles in Oncology Under Newly Established Cooperative Scientific Agreement with the Medical University of Graz

Retrieved on: 
Monday, July 25, 2022

Under the agreement, Lifespin will be able to analyze and capture the metabolic profiles from more than 25,000 longitudinal human blood samples involving approximately 4,800 oncological patients.

Key Points: 
  • Under the agreement, Lifespin will be able to analyze and capture the metabolic profiles from more than 25,000 longitudinal human blood samples involving approximately 4,800 oncological patients.
  • Lifespin has already gathered a significant database of health profiles in oncology.
  • Lifespin GmbH is a deep data company that is mapping the metabolic profiles of human health.
  • Lifespin has standardized the baseline for human health to detect distinct deviations in the human metabolism caused by diseases.

Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment

Retrieved on: 
Wednesday, June 29, 2022

Reflow Medical, Inc. , a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease.

Key Points: 
  • Reflow Medical, Inc. , a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease.
  • View the full release here: https://www.businesswire.com/news/home/20220628006094/en/
    The Temporary Spur Stent System is a novel device with a patented retrievable stent system.
  • On behalf of the team here at Reflow, we offer sincere thanks and gratitude for the partnership with Professor Brodmann and her team, commented Isa Rizk, CEO and Co-founder of Reflow Medical.
  • Reflow Medical, Inc. is a private company focused on empowering physicians through the design and development of innovative and effective technologies for cardiovascular disease.

ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE

Retrieved on: 
Wednesday, May 18, 2022

Cambridge, UK, 18 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing todays therapies to enable healthier lives, today announces that it will host a key opinion leader webinar entitled The Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care, on Thursday 26 May, 2022, at 15:00-16:30 BST.

Key Points: 
  • Cambridge, UK, 18 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing todays therapies to enable healthier lives, today announces that it will host a key opinion leader webinar entitled The Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care, on Thursday 26 May, 2022, at 15:00-16:30 BST.
  • While rapid acting insulins have become standard of care, there are currently no concentrated rapid acting insulin products available to patients to enable reduced injection volumes, fewer injections per day and the potential for improved blood glucose control.
  • Arecors webinar will bring together four world-class experts in the field of diabetes care, who will discuss the AT278 clinical data as well as the clinical and patient need.
  • Davida Kruger, Certified Diabetes Nurse Practitioner, Henry Ford Health System, Division of Endocrinology, Detroit, USA, will focus on the benefits of concentrated insulin from the patient perspective.

BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals

Retrieved on: 
Wednesday, May 18, 2022

The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.

Key Points: 
  • The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.
  • The joint proposal by BC Platforms, Euformatics and Oncompass Medicine was evaluated by leading experts and selected for funding.
  • Oncompass was the first to develop a software as a medical device based on artificial intelligence that proved to improve therapeutic decisions in precision oncology.
  • Oncompass also provides end-to-end services for oncology centers that wish to provide precision oncology to their patients.